Tempest Therapeutics Inc (TPST) Short-Term Debt to Equity

The publication of positive data regarding the oncology portfolio creates powerful catalysts, while development costs are already priced in, as confirmed by the 0.00 metric. The price trend shown below helps track the dynamics of Tempest Therapeutics (TPST), which develops small molecules for the targeted destruction of tumors. Growth prospects are tied to FDA approval and the success of liver cancer therapy, making the company an attractive acquisition target for pharma behemoths.

The ratio determines the extent to which short-term liabilities are covered by own funds, measuring liquidity risk and the company's dependence on short-term borrowed capital. For Tempest Therapeutics (TPST), which is scaling TPST-1120 trials, the historical share of short-term loans in capital confirms the ability to finance pipeline expansion without a critical debt load, ensuring financial stability while capturing the cancer therapy market.